Journal
INTEGRATIVE CANCER THERAPIES
Volume 22, Issue -, Pages -Publisher
SAGE PUBLICATIONS INC
DOI: 10.1177/15347354221150787
Keywords
Neuroblastoma; ketogenic diet; childhood malignancies; Warburg Effect; adjuvant therapy; nutritional therapy
Categories
Ask authors/readers for more resources
The ketogenic diet was originally used for drug-resistant epileptic patients and has since been studied for its therapeutic potential in various diseases. However, its effectiveness as an antitumor nutritional therapy for Neuroblastoma remains uncertain.
The ketogenic diet (KD) was initially used in 1920 for drug-resistant epileptic patients. From this point onward, ketogenic diets became a pivotal part of nutritional therapy research. To date, KD has shown therapeutic potential in many pathologies such as Alzheimer's disease, Parkinson's disease, autism, brain cancers, and multiple sclerosis. Although KD is now an adjuvant therapy for certain diseases, its effectiveness as an antitumor nutritional therapy is still an ongoing debate, especially in Neuroblastoma. Neuroblastoma is the most common extra-cranial solid tumor in children and is metastatic at initial presentation in more than half of the cases. Although Neuroblastoma can be managed by surgery, chemotherapy, immunotherapy, and radiotherapy, its 5-year survival rate in children remains below 40%. Earlier studies have proposed the ketogenic diet as a possible adjuvant therapy for patients undergoing treatment for Neuroblastoma. In this study, we seek to review the possible roles of KD in the treatment of Neuroblastoma.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available